Low Glycemic Load Diet in Patients With Stage I-III Colon Cancer

Status Completed

Clinical Trial Summary

This pilot clinical trial studies the feasibility of a low glycemic load diet in patients with stage I-III colon cancer. A low glycemic load diet includes foods that have low scores on the glycemic index. The glycemic index is a scale that measures how much a certain carbohydrate causes a person's blood sugar to rise. A low glycemic load diet may help decrease the chance of cancer coming back and improve the survival in patients with colon cancer.

Clinical Trial Description

PRIMARY OBJECTIVES:

I. To determine the feasibility of following a low or medium glycemic load diet in patients with stage I-III (local-regional) colon cancer.

SECONDARY OBJECTIVES:

I. To determine patient-reported acceptability of diet. II. To determine nutritionist resources utilized. III. To evaluate the effect of lowering dietary glycemic load on body mass index (BMI), lipid metabolism and pro-oncogenic intermediaries of cellular metabolism.

OUTLINE: Patients are sequentially enrolled in 1 of 4 possible cohorts as needed based on the feasibility of the prior cohort.

COHORT 1: Patients follow a low glycemic load diet with standard dietary intervention (contact with nutritionist in person every 2 weeks with phone contact on the alternating weeks) for 12 weeks.

COHORT 2: Patients follow a low glycemic load diet with intensified dietary intervention (contact with nutritionist in person every week) for 12 weeks.

COHORT 3: Patients follow a medium glycemic load diet with standard dietary intervention for 12 weeks.

COHORT 4: Patients follow a medium glycemic load diet with intensified dietary intervention for 12 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02129218
Study type	Interventional
Source	Case Comprehensive Cancer Center
Contact
Status	Completed
Phase	N/A
Start date	February 16, 2015
Completion date	July 10, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00025337` - Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated	Phase 3
Active, not recruiting	`NCT04164069` - Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab	Phase 1
Not yet recruiting	`NCT05870800` - Neoadjuvant Chemoimmunotherapy for Resectable Non-Metastatic Proficient Mismatch Repair (PMMR) Colon Cancer	Phase 2
Recruiting	`NCT02280278` - Cytokine-induced Killer Cell Immunotherapy for Surgical Resected Stage III Colorectal Cancer Patients After Chemotherapy	Phase 3
Completed	`NCT01191684` - Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer	Phase 1
Completed	`NCT00551421` - Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer	Phase 1/Phase 2
Recruiting	`NCT03958435` - Real-world Retrospective Data Analysis of Adjuvant Therapy for Patients With Stage II-III Colon Cancer After Radical Surgery
Completed	`NCT01890213` - Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer	Phase 1
Completed	`NCT00028496` - Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer	Phase 1
Active, not recruiting	`NCT03255434` - LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy	Phase 2
Completed	`NCT01126346` - Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)	N/A
Terminated	`NCT00087191` - EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer	N/A
Completed	`NCT00003835` - Combination Chemotherapy in Treating Patients With Stage III Colon Cancer	Phase 3
Recruiting	`NCT05062889` - Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients	Phase 2
Recruiting	`NCT04416490` - Oxaliplatin Adjuvant Chemotherapy After Curative Resection of Primary Colon Cancer
Active, not recruiting	`NCT02836977` - Maintenance Tegafur-uracil Versus Observation Following Adjuvant Oxaliplatin-based Regimen in Patients With Stage III Colon Cancer After Radical Resection	N/A
Completed	`NCT00005818` - SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer	Phase 1/Phase 2
Completed	`NCT00019006` - Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer	Phase 1
Recruiting	`NCT05174169` - Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease	Phase 2/Phase 3
Not yet recruiting	`NCT06287814` - French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC)